On June 9, 2020 Oncology Venture A/S (Nasdaq First North Stockholm: OV.ST) ("OV" or the "Company") reported that it has called upon Global Corporate Finance (GCF) to invest SEK 10 million in a directed shared issue in accordance with the Company’s share subscription agreement with GCF (Press release, Oncology Venture, JUN 9, 2020, View Source [SID1234560941]). The draw-down notice was issued to GCF on June 9, and the share subscription price shall be calculated as 95% of the daily volume weighted average price (VWAP) of the Company’s shares for the five consecutive trading days following the date of the draw down notice.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The investment is the first investment tranche of up to a total of five such tranches Oncology Venture may request from Global Corporate Finance (New York City, NY, U.S.). Each investment tranche can total up to SEK 10 million.